AdventRx Acquires SynthRx for Late-Stage Sickle Cell Disease Drug
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 2 (Table of Contents)
Published: 23 Feb-2011
DOI: 10.3833/pdr.v2011.i2.1437 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
AdventRx Pharmaceuticals has agreed to acquire the privately held biotech SynthRx in an all-stock deal that will see the company move into the sickle cell disease (SCD) therapy area...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS